Morclofone

Morclofone

SCHEMBL554800

COc1cc(C(=O)c2ccc(Cl)cc2)cc(OC)c1OCCN1CCOCC1

nearest known ligand 0.60

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 0.60
SMN1; SMN2 Q16637 2/20 0.54
TSHR P16473 3/20 0.51
CYP2D6 P10635 2/20 0.51
ALDH1A1 P00352 5/20 0.50
MAPT P10636 2/20 0.50
MAPK1 P28482 2/20 0.50
KMT2A Q03164 2/20 0.50
USP2 O75604 1/20 0.50
LMNA P02545 2/20 0.49
KDM4E B2RXH2 3/20 0.48
TP53 P04637 2/20 0.48
CYP2C9 P11712 1/20 0.48
MEN1 O00255 1/20 0.48
GAA P10253 1/20 0.48
KCNA5 P22460 1/20 0.47
DRD3 P35462 1/20 0.47
DRD2 P14416 1/20 0.47
HPGD P15428 1/20 0.47
HTT P42858 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4711038 0.83 SYK (0.70) SYKSMN1; SMN2TSHRCYP2D6ALDH1A1
Morclofone SCHEMBL28086404 0.82 KMT2A (0.41) SYKSMN1; SMN2TSHRCYP2D6ALDH1A1
SCHEMBL2088816 0.82 SYK (0.68) SYKSMN1; SMN2TSHRCYP2D6ALDH1A1
SCHEMBL3930808 0.76 KDM4E (0.61) SYKSMN1; SMN2TSHRCYP2D6ALDH1A1
SCHEMBL23195558 0.76 KDM4E (0.61) SYKSMN1; SMN2TSHRCYP2D6ALDH1A1
SCHEMBL10196165 0.76 SYK (1.00) SYKTSHRCYP2D6ALDH1A1KMT2A
SCHEMBL4714483 0.75 SYK (0.59) SYKSMN1; SMN2TSHRCYP2D6ALDH1A1
SCHEMBL3930162 0.75 SMN1; SMN2 (0.65) SYKSMN1; SMN2CYP2D6ALDH1A1MAPT
SCHEMBL23195583 0.75 SMN1; SMN2 (0.65) SYKSMN1; SMN2TSHRCYP2D6ALDH1A1
SCHEMBL4267324 0.75 CYP2D6 (0.60) SYKSMN1; SMN2TSHRCYP2D6ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 478 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250255781-A1 PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS BRISTOL-MYERS SQUIBB COMPANY (US) 2025-08-14 US claimed
US-12296043-B2 Liquisoft capsules PATHEON SOFTGELS INC. (US) 2025-05-13 US claimed
EP-4510999-A1 PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS Bristol-Myers Squibb Company (US) 2025-02-26 EP claimed
US-20240165020-A1 LIQUISOFT CAPSULES PATHEON SOFTGELS INC (US) 2024-05-23 US claimed
EP-4360653-A2 LIQUISOFT CAPSULES Patheon Softgels Inc. (US) 2024-05-01 EP claimed
US-11872307-B2 Liquisoft capsules PATHEON SOFTGELS INC. (US) 2024-01-16 US claimed
EP-3682872-B1 LIQUISOFT CAPSULES PATHEON SOFTGELS INC (US) 2024-01-03 EP claimed
WO-2023205619-A1 PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS BRISTOL-MYERS SQUIBB COMPANY (US) 2023-10-26 WO claimed
CN-107708716-B Methods and systems for microbiome-derived diagnosis and treatment of conditions associated with microbiome taxonomic features 普梭梅根公司 2022-12-06 CN claimed
US-20220211616-A1 LIQUISOFT CAPSULES PATHEON SOFTGELS INC (US) 2022-07-07 US claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 US claimed
EP-1651184-A1 FAST DISSOLVING ORALLY CONSUMABLE FILMS CONTAINING PHARMACEUTICALLY ACTIVE AGENTS Warner-Lambert Company LLC (US) 2006-05-03 EP claimed
CN-1750809-A Fast dissolving orally consumable films containing pharmaceutically active agents WARNER LAMBERT CO (US) 2006-03-22 CN claimed
WO-2004096174-A1 FAST DISSOLVING ORALLY CONSUMABLE FILMS CONTAINING PHARMACEUTICALLY ACTIVE AGENTS WARNER-LAMBERT COMPANY LLC (US) 2004-11-11 WO claimed
US-20030206942-A1 Fast dissolving orally consumable films containing an antitussive and a mucosa coating agent MCNEIL-PPC, INC 2003-11-06 US claimed
EP-1336602-A1 Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases Scaramuzzino, Giovanni (IT) 2003-08-20 EP claimed
CN-1294519-A Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient INPHARMA SA (CH) 2001-05-09 CN claimed
EP-1073470-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2001-02-07 EP claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 WO claimed